CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186680
First received: September 14, 2005
Last updated: February 26, 2010
Last verified: February 2010

September 14, 2005
February 26, 2010
September 1996
June 2005   (final data collection date for primary outcome measure)
Feasibility and safety [ Time Frame: unknown ] [ Designated as safety issue: Yes ]
Feasiblity and safety
Complete list of historical versions of study NCT00186680 on ClinicalTrials.gov Archive Site
  • efficiency of mobilization [ Time Frame: unknown ] [ Designated as safety issue: No ]
  • tumor contamination [ Time Frame: unknown ] [ Designated as safety issue: No ]
  • - efficiency of mobilization
  • - tumor contamination
Not Provided
Not Provided
 
CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment

Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment

Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
Procedure: high dose chemo then auto hematopoietic cell transplant
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
99
June 2005
June 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:- stage IV breast cancer

  • primary breast cancer does not express CD34+
  • adequate organ function
  • no evidence of active infection

Exclusion Criteria:- chemotherapy within 4 weeks

- CNS disease

Both
19 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00186680
BMT86, BMT86
Not Provided
Ginna Laport, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: Ginna Laport Stanford University
Stanford University
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP